|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Clinuvel Pharmaceuticals (CUV.AX)
1ST TIMEFRAME TREND
Trading: HOLD @ $26.36
Signal Strength: WEAK
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.
Clinuvel Pharmaceuticals (ASX:CUV) has a neutral trend in the short term timeframe. The buyers & sellers are not dominant enough to swing the daily trend
The Tricklar short term trend indicator (T1) highlights the high points and low points associated with the individual bars. As such, successive rallies penetrating preceding high points whilst cancelling preceding lower troughs offer a BULLISH indication in the second time frame. Conversely, failure of rallies to penetrate previous Lower peaks whilst maintaining prices below the previous lower troughs indicates BEARISH trends in the second timeframe.
Calculation: Tricklar short trend (T1):
1) [BULLISH] An uptrend is a succession of higher highs and higher lows;
2) [BEARISH] A downtrend is a succession of lower highs and lower lows;
PROFILE: Clinuvel Pharmaceuticals (CUV.AX)
Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.
|WSA Western Areas||2.79||3.3||3,344,659||1||BULLISH|
|ONT 1300 Smiles||6.34||2.3||1,400||1||BULLISH|
|RIC Ridley Corporation||1.11||2.3||35,743||1||BULLISH|
|CAJ Capitol Health||0.24||2.2||83,788||1||BULLISH|
|CWP Cedar Woods Properties||7.5||2||34,918||1||BULLISH|
|CLW Charter Hall Long Wale||5.85||1.6||2,114,407||1||BULLISH|
|SWM Seven West Media||0.37||1.4||2,805,282||1||BULLISH|